Weekly Funding Opportunities

[Med Research]

Johnson & Johnson Quickfire Challenge: Maternal Health<https://jlabs.jnjinnovation.com/quickfire-challenges/maternal-health-quickfire-challenge#paragraph-11316>
Of the nearly 700 women who die from pregnancy-related complications per year, the CDC estimates that three in five are preventable and half the injuries could be avoided with proper care. While death and complication rates around the globe are declining, they are rising in the United States, making it the most dangerous place in the developed world to give birth. To address the problem, grants of up to $200,000 will be awarded to innovators in support of ideas aimed at improving pregnancy, birth, and postpartum care for women, making birth safer in the United States and potentially changing the trajectory of health for a lifetime. In addition, awardees will receive access to the global JLABS network and mentorship from experts at the Johnson & Johnson Family of Companies. JLABS has shown a particular interest in the following areas: consumer healthcare; community health approaches; health technologies; medical devices; patient care; pharmaceuticals; and cross-sector Initiatives. Priority will be given to science-based potential innovations backed by data.
Due June 19, 2020. Med-RA deadline to receive draft documents: June 8.

Congressionally Directed Medical Research Programs
Peer Reviewed Alzheimer's Research Program<https://cdmrp.army.mil/funding/prarp>
Convergence Science Research Award
Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020.
Innovation in Care and Support Award
Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020.
Research Partnership Award
Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020.
Accelerating Diagnostics for Traumatic Brain Injury Research Award
Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020.
Leveraging Approaches for Innovation in Care and Support Award
Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020.
Med-RA deadline to receive draft documents for pre-application due date: June 9.
Epilepsy Research Program<https://cdmrp.army.mil/funding/erp>
Idea Development Award
Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020.
Quality of Life Award
Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020.
Research Partnership Award
Pre-application (letter of intent): June 22, 2020. Application: July 21, 2020.
Med-RA deadline to receive draft documents for pre-application due date: June 9.
Vision Research Program<https://cdmrp.army.mil/funding/vrp>
Focused Translational Team Science Award
Pre-application (preproposal): July 28, 2020. Application: November 18, 2020.
Investigator Initiated Research Award
Pre-application (preproposal): July 28, 2020. Application: November 18, 2020.
Translational Research Award
Pre-application (preproposal): July 28, 2020. Application: November 18, 2020.
Med-RA deadline to receive draft documents for pre-application due date: July 20.

NCCIH Natural Product Awards / Cooperative Agreement (R61/R33, R33, U01 Clinical Trial Required)
These Funding Opportunity Announcements (FOAs) encourage applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics) that have a strong scientific premise to justify further clinical testing. Under these FOAs, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. Clinical trials submitted under these FOAs are expected to be hypothesis-based, milestone-driven, and directly related to the research priorities and mission of NCCIH. These FOAs will not support efficacy or effectiveness trials, nor will they support trials to test natural products for the treatment or prevention of cancer.
NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award R61/R33<https://grants.nih.gov/grants/guide/pa-files/PAR-20-218.html>
This FOA will provide up to 3 years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural product’s effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulation. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. A maximum of 5 years will be supported by the two phases of the R61/R33 award.
NCCIH Natural Product Early Phase Clinical Trial Award R33<https://grants.nih.gov/grants/guide/pa-files/par-20-217.html>
This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted.
NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement U01<https://grants.nih.gov/grants/guide/pa-files/par-20-216.html>
This FOA invites cooperative agreement applications for investigator-initiated mid-phase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product’s mechanism of action will this preliminary data requirement be waived.
Applications submitted to this FOA should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy study.
Due July 20,2020; February 01, 2021; October 01, 2021; June 01, 2022; and February 01, 2023. Med-RA deadline to receive draft documents for July 20, 2020 due date: July 7.

NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-020.html>
The NIH Director’s New Innovator Award Program<https://commonfund.nih.gov/newinnovator/index> supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Director’s New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program<https://commonfund.nih.gov/highrisk/> of the NIH Common Fund<https://commonfund.nih.gov/>.
Due August 21, 2020. Med-RA deadline to receive draft documents: August 10.

NIH Director’s Early Independence Awards (DP5 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-014.html>
The NIH Director's Early Independence Award<https://commonfund.nih.gov/earlyindependence> supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's Early Independence Award is a component of the High-Risk, High-Reward Research program<https://commonfund.nih.gov/highrisk> of the NIH Common Fund<https://commonfund.nih.gov/>.
Due September 4, 2020. Med-RA deadline to receive draft documents: August 24.

NIH Director’s Emergency Early Independence Awards (DP5 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-021.html>
This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act<https://www.congress.gov/bill/116th-congress/senate-bill/3548/text>. The NIH Director's Early Independence Award<https://commonfund.nih.gov/earlyindependence> (a component of the High-Risk, High-Reward Research program<https://commonfund.nih.gov/highrisk> of the NIH Common Fund<https://commonfund.nih.gov/>) supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act<https://www.congress.gov/bill/116th-congress/senate-bill/3548/text> to support a total of 5-10 Early Independence Awards (through this FOA) or Transformative Research Awards<https://commonfund.nih.gov/TRA> (through RFA-RM-20-020) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual.
Due September 4, 2020. Med-RA deadline to receive draft documents: August 24.

NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-011.html>
The NIH Director’s Pioneer Award Program<https://commonfund.nih.gov/pioneer> supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. The NIH Director’s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program<http://commonfund.nih.gov/highrisk/> of the NIH Common Fund<http://commonfund.nih.gov/>.
Due September 11, 2020. Med-RA deadline to receive draft documents: August 31.

NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-013.html>
The NIH Director’s Transformative Research Award Program<https://commonfund.nih.gov/TRA> supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications are welcome in all topics relevant to the broad mission of NIH, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Director’s Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program<http://commonfund.nih.gov/highrisk/> of the NIH Common Fund<http://commonfund.nih.gov/>.
Due September 30, 2020. Med-RA deadline to receive draft documents: September 21.

NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-020.html>
This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act<https://www.congress.gov/bill/116th-congress/senate-bill/3548/text>. The NIH Director’s Transformative Research Award Program<https://commonfund.nih.gov/TRA> supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. The NIH Director’s Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program<http://commonfund.nih.gov/highrisk/> of the NIH Common Fund<http://commonfund.nih.gov/>.
Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act<https://www.congress.gov/bill/116th-congress/senate-bill/3548/text> to support a total of 5-10 Transformative Research Awards (through this FOA) or Early Independence Awards<https://commonfund.nih.gov/earlyindependence> (through RFA-RM-20-021) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual.
Due September 30, 2020. Med-RA deadline to receive draft documents: September 21.

Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences (DMS/NIGMS)<https://www.nsf.gov/pubs/2020/nsf20575/nsf20575.htm>
This program is designed to support research in mathematics and statistics addressing important questions in the biological and biomedical sciences. Research projects that apply routine mathematical or statistical techniques to solve biological or biomedical problems are not appropriate for this competition, and they may be submitted to NIH through other mechanisms (https://grants.nih.gov/grants/oer.htm). Similarly, mathematical, or statistical research projects that are not tied to any specific biological or biomedical problem should be submitted to the appropriate programs at NSF. Proposals designed to create new software tools based solely on existing models and methods will not be accepted in this competition. Additionally, proposals to create models to characterize and analyze a particular biosystem without novel advances in mathematics or statistics are very low priority for the program, and therefore, submission of such proposals are highly discouraged. Successful proposals are expected to address clearly stated biological/biomedical questions, make a compelling case for and develop innovative mathematical/computational/statistical methods or integrate disparate mathematical/computational/statistical fields, and articulate a well-defined plan for the mathematics or statistics to drive biological/biomedical discovery within the funded period. A direct relationship between a biological/biomedical application and the mathematical/computational/statistical work is required. Research collaborations that include scientists from both the life and mathematical science communities are expected. Proposals from single investigators must provide convincing evidence that the principal investigator has the necessary expertise in both mathematics/statistics and life sciences. While projects from existing collaborations are allowed, we strongly encourage exploratory, high-risk and high-reward Track 1 proposals from new teams of researchers. All proposals in response to this solicitation must be responsive to one or more of the research areas of NIGMS (https://www.nigms.nih.gov/research-areas). Proposals not conforming to these areas will be returned without review. Proposals that are of biological/biomedical nature but not within the scope of NIGMS (such as proposals that focus on a specific disease or physiological system) should be submitted to NIH under the parent FOA (https://grants.nih.gov/grants/guide/pa-files/PA-19-056.html).
Due September 18, 2020. Med-RA deadline to receive draft documents: September 8.

Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-21-006.html>
This Funding Opportunity Announcement (FOA) invites grant applications that address priority gaps in understanding the role of nutrition in the care and development of preterm infants.
Due November 30, 2020. Med-RA deadline to receive draft documents: November 16.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200528/4789c952/attachment.html>